Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Pityriasis rubra pilaris-like graft-vs-host disease following allogeneic stem cell transplant in two patients.

Wang JY, Tabata MM, Pugliese S, Phillips D, Kim J, Weng WK, Kwong BY.

Clin Case Rep. 2019 Nov 14;7(12):2491-2494. doi: 10.1002/ccr3.2458. eCollection 2019 Dec.

2.

Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.

Spinner MA, Kennedy VE, Tamaresis JS, Lavori PW, Arai S, Johnston LJ, Meyer EH, Miklos DB, Muffly LS, Negrin RS, Rezvani AR, Shizuru JA, Weng WK, Hoppe RT, Strober S, Lowsky R.

Blood Adv. 2019 Aug 27;3(16):2454-2464. doi: 10.1182/bloodadvances.2019000297.

3.

Targeting CD137 enhances the efficacy of cetuximab.

Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R, Troutner E, Richards L, Rajapaska A, Hebb J, Chester C, Waller E, Ostashko A, Weng WK, Chen L, Czerwinski D, Fu YX, Sunwoo J, Levy R.

J Clin Invest. 2019 Jun 3;129(6):2595. doi: 10.1172/JCI129689. Epub 2019 Jun 3. No abstract available.

4.

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.

Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, Colevas AD, Weng WK, Clarke MF, Carlson RW, Stockdale FE, Mollick JA, Chen L, Levy R.

J Clin Invest. 2019 Jun 3;129(6):2595. doi: 10.1172/JCI129688. Epub 2019 Jun 3. No abstract available.

5.

Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients.

Meyer EH, Laport G, Xie BJ, MacDonald K, Heydari K, Sahaf B, Tang SW, Baker J, Armstrong R, Tate K, Tadisco C, Arai S, Johnston L, Lowsky R, Muffly L, Rezvani AR, Shizuru J, Weng WK, Sheehan K, Miklos D, Negrin RS.

JCI Insight. 2019 May 16;4(10). pii: 127244. doi: 10.1172/jci.insight.127244. eCollection 2019 May 16.

6.

Volumetric Modulated Arc Therapy and 3-Dimensional Printed Bolus in the Treatment of Refractory Primary Cutaneous Gamma Delta Lymphoma of the Bilateral Legs.

Obeid JP, Gutkin PM, Lewis J, Skinner L, Wang EB, Khodadoust MS, Kim YH, Weng WK, Hoppe RT, Hiniker SM.

Pract Radiat Oncol. 2019 Jul - Aug;9(4):220-225. doi: 10.1016/j.prro.2019.02.016. Epub 2019 Mar 2. No abstract available.

PMID:
30836188
7.

Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome.

Dai J, Almazan TH, Hong EK, Khodadoust MS, Arai S, Weng WK, Kim YH.

JAMA Dermatol. 2018 Jun 1;154(6):728-730. doi: 10.1001/jamadermatol.2018.0884. No abstract available.

8.

Infusion of donor-derived CD8+ memory T cells for relapse following allogeneic hematopoietic cell transplantation.

Muffly L, Sheehan K, Armstrong R, Jensen K, Tate K, Rezvani AR, Miklos D, Arai S, Shizuru J, Johnston L, Meyer E, Weng WK, Laport GG, Negrin RS, Strober S, Lowsky R.

Blood Adv. 2018 Mar 27;2(6):681-690. doi: 10.1182/bloodadvances.2017012104.

9.

HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.

Spinner MA, Fernández-Viña M, Creary LE, Quinn O, Elder L, Arai S, Johnston LJ, Meyer EH, Miklos DB, Muffly LS, Negrin RS, Shizuru JA, Weng WK, Laport GG, Strober S, Lowsky R, Rezvani AR.

Blood Adv. 2017 Jul 25;1(17):1347-1357. doi: 10.1182/bloodadvances.2017007716. eCollection 2017 Jul 25.

10.

Effect of voriconazole on risk of nonmelanoma skin cancer after hematopoietic cell transplantation.

Kuklinski LF, Li S, Karagas MR, Weng WK, Kwong BY.

J Am Acad Dermatol. 2017 Oct;77(4):706-712. doi: 10.1016/j.jaad.2017.06.032. Epub 2017 Aug 2.

11.

Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation.

Veeraputhiran M, Yang L, Sundaram V, Arai S, Lowsky R, Miklos D, Meyer E, Muffly L, Negrin R, Rezvani A, Shizuru J, Weng WK, Johnston L.

Biol Blood Marrow Transplant. 2017 Oct;23(10):1744-1748. doi: 10.1016/j.bbmt.2017.06.005. Epub 2017 Jun 28.

12.

Gain of CD26 expression on the malignant T-cells in relapsed erythrodermic leukemic mycosis fungoides.

Cedeno-Laurent F, Wysocka M, Obstfeld AE, Novoa RA, Vittorio CC, Kim EJ, Weng WK, Rook AH.

J Cutan Pathol. 2017 May;44(5):462-466. doi: 10.1111/cup.12899. Epub 2017 Feb 10.

PMID:
28083948
13.

Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2.

Ungewickell A, Bhaduri A, Rios E, Reuter J, Lee CS, Mah A, Zehnder A, Ohgami R, Kulkarni S, Armstrong R, Weng WK, Gratzinger D, Tavallaee M, Rook A, Snyder M, Kim Y, Khavari PA.

Nat Genet. 2015 Sep;47(9):1056-60. doi: 10.1038/ng.3370. Epub 2015 Aug 10.

14.

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.

Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, Rozati S, Nagpal S, Krathen M, Reddy S, Hoppe RT, Nguyen-Lin A, Weng WK, Armstrong R, Pulitzer M, Advani RH, Horwitz SM.

J Clin Oncol. 2015 Nov 10;33(32):3750-8. doi: 10.1200/JCO.2014.60.3969. Epub 2015 Jul 20.

15.

Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile.

Percival MM, Medeiros BC, Tian L, Robeson S, Laport GG, Johnston LJ, Shizuru JA, Miklos DB, Arai S, Weng WK, Negrin RS, Lowsky R.

Bone Marrow Transplant. 2015 Jul;50(7):1004-1006. doi: 10.1038/bmt.2015.62. Epub 2015 Apr 20. No abstract available.

16.

A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia.

Strati P, Tong WG, Vitale C, Wierda WG, O'Brien S, Brown JR, Weng WK, Kipps T, Keating MJ, Ferrajoli A.

Leuk Lymphoma. 2015 Jun;56(6):1878-80. doi: 10.3109/10428194.2014.974049. Epub 2014 Nov 20. No abstract available.

17.

Targeting CD137 enhances the efficacy of cetuximab.

Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R, Troutner E, Richards L, Rajapaska A, Hebb J, Chester C, Waller E, Ostashko A, Weng WK, Chen L, Czerwinski D, Fu YX, Sunwoo J, Levy R.

J Clin Invest. 2014 Jun;124(6):2668-82. doi: 10.1172/JCI73014. Epub 2014 May 16. Retraction in: J Clin Invest. 2019 Jun 03;129(6):2595.

18.

Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.

Benjamin J, Chhabra S, Kohrt HE, Lavori P, Laport GG, Arai S, Johnston L, Miklos DB, Shizuru JA, Weng WK, Negrin RS, Lowsky R.

Biol Blood Marrow Transplant. 2014 Jun;20(6):837-43. doi: 10.1016/j.bbmt.2014.02.023. Epub 2014 Mar 7.

19.

Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma.

Weng WK, Armstrong R, Arai S, Desmarais C, Hoppe R, Kim YH.

Sci Transl Med. 2013 Dec 4;5(214):214ra171. doi: 10.1126/scitranslmed.3007420.

20.

Cancer vaccines and T cell therapy.

Rezvani K, Brody JD, Kohrt HE, Logan AC, Advani R, Czerwinski DK, Weng WK, Negrin RS, Carlton V, Faham M, Levy R, Barrett J.

Biol Blood Marrow Transplant. 2013 Jan;19(1 Suppl):S97-S101. doi: 10.1016/j.bbmt.2012.09.020. Epub 2012 Oct 3. Review. No abstract available.

Supplemental Content

Loading ...
Support Center